Posts tagged Jason Mills
Canaccord ups STAAR Surgical price target to $9

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $9 from $7, but maintained its “hold” rating after the company reported fourth quarter results. The stock closed at $10.18 on March 2.

Read More
Canaccord ups AtriCure price target to $23

Canaccord Genuity raised its price target for AtriCure (NASDAQ:ATRC) to $23 from $21 after the company reported third quarter results. The stock is trading at $17.74, up $2.54, at midday on Friday.

The third quarter represented “sentiment-changing results for an under-appreciated, under-valued, high margin med-tech growth story,” writes analyst Jason Mills. “Bottom line: buy this stock,” he added.

Read More
Canaccord ups CryoLife price target to $23.50

Canaccord Genuity raised its price target for CryoLife (NYSE:CRY) to $23.50 from $17.50 after the company reported third quarter results. The stock is changing hands at $17.10 on Thursday afternoon.

Analyst Jason Mills writes that CryoLife posted a significant earnings beat on solid sales growth, higher gross margins and operating expense leverage flowing through to the bottom line.

Read More
Canaccord starts Merit Medical at buy

Canaccord Genuity initiated coverage of Merit Medical Systems (NASDAQ:MMSI) with a “buy” rating and $27 price target. The stock closed at $20.51 on Monday.

Merit develops, manufactures, and commercializes a vast array of medical devices, targeting interventional and diagnostic procedures.

Read More
Canaccord upgrades Endologix to buy

Canaccord Genuity has upgraded Endologix (NASDAQ:ELGX) to “buy” from “hold” and raised its price target to $15.50 from $11.25. The stock closed at $12.68 on Friday.

The company is developing Nellix as an endovascular aneurysm sealing (EVAS) system designed for the treatment of infrarenal abdominal aortic aneurysm (AAA) and is the only technology whose operating principle is centered on sealing the aneurysm sac.

Read More
Canaccord ups Spectranetics price target to $23.50

Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday.

“Our bullish conviction heading into the Q1 print was validated by the strong quarterly performance that reflected a continuation of the positive trends from the second half of 2015,” writes analyst Jason Mills.

Read More
Canaccord starts CryoLife at buy

Canaccord Genuity has launched coverage of CryoLife (NYSE:CRY) with a “buy” rating and $14 yearend price target. The stock closed at $11 on Tuesday.

“We recommend small-cap GARP (growth at a reasonable price) investors build positions in CryoLife, which is actively building a cardiac surgery-focused company through targeted acquisitions that augment its strong, existing core franchise and strategic divestitures,” writes analyst Jason Mills.

Read More
Canaccord downgrades AngioDynamics to hold

Canaccord Genuity has downgraded AngioDynamics (NASDAQ:ANGO) to “hold” from “buy” and reduced its price target to $13 from $14.50, following the abrupt departure of CEO, Joe DeVivo, “which we think will heighten investor concern near term, and increase uncertainty.” The stock closed at $12.14 on Monday.

“What’s more, this change compounds myriad existing challenges that have produced sluggish and inconsistent performance in the business over the past year,” writes analyst Jason Mills.

Read More